Showing results (1-10 of 9) with videos related to
Sort By:
Pageof 1
Child: Care, Health and Development|November 1, 1995
Talking with children about death and dyingS A Pettle, C M BrittenCancer Immunology, Immunotherapy : CII|September 30, 2005
Cancer immunotherapy 2005: Mainz, Germany, 12-13 May 2005C M Britten, C Gouttefangeas, S KreiterGene Therapy|March 4, 2011
Selective uptake of naked vaccine RNA by dendritic cells is driven by macropinocytosis and abrogated upon DC maturationM Diken, S Kreiter, A Selmi, et al.Cancer Immunology, Immunotherapy : CII|January 7, 2010
Serum is not required for ex vivo IFN-gamma ELISPOT: a collaborative study of different protocols from the European CIMT Immunoguiding ProgramA Mander, C Gouttefangeas, C Ottensmeier, et al.British Journal of Cancer|October 15, 2014
Translation of genomics-guided RNA-based personalised cancer vaccines: towards the bedsideV Boisguérin, J C Castle, M Loewer, et al.European Journal of Cancer (Oxford, England : 1990)|January 27, 2009
Improving the efficacy of cancer immunotherapyJ Copier, A G Dalgleish, C M Britten, et al.Cancer Immunology, Immunotherapy : CII|November 7, 2009
Performance of serum-supplemented and serum-free media in IFNgamma Elispot Assays for human T cellsSylvia Janetzki, L Price, C M Britten, et al.Cancer Immunology, Immunotherapy : CII|November 17, 2010
Minimal information about T cell assays: the process of reaching the community of T cell immunologists in cancer and beyondC M Britten, S Janetzki, S H van der Burg, et al.Cancer Immunology, Immunotherapy : CII|August 28, 2007
The CIMT-monitoring panel: a two-step approach to harmonize the enumeration of antigen-specific CD8+ T lymphocytes by structural and functional assaysC M Britten, C Gouttefangeas, M J P Welters, et al.Pageof 1